Does Removing More Mesentery Reduce Crohn’s Recurrence After Ileocolic Resection (MESOCOLIC Trial): Gastroenterology | September 2026

Introduction:

Surgery is frequently required during the course of Crohn’s disease (CD), but the optimal extent of mesenteric resection remains controversial.

Traditionally, Crohn’s surgery has emphasised bowel preservation with relatively limited mesenteric excision. Increasing evidence, however, suggests that the mesentery, creeping fat, lymphatics and associated inflammatory pathways may actively participate in Crohn’s disease biology.

The randomized MESOCOLIC trial compared extensive mesenteric excision (EME) with limited mesenteric excision (LME) during ileocolic resection. Its mid- to long-term results suggest an intriguing benefit of EME for endoscopic recurrence, although a reduction in surgical recurrence has not yet been demonstrated.

Why was this study needed?

After ileocolic resection, postoperative recurrence remains common despite removal of the macroscopically diseased bowel.

The unresolved surgical question is:

Should surgery remove only the affected intestine with limited mesentery—or should the diseased mesentery also be more extensively excised?

Biologically, the question is plausible because the Crohn’s mesentery contains:

Creeping fat

Activated fibroblasts

Inflammatory and immune cells

Lymphatic abnormalities

Neural elements

Potential pathways linking microbial translocation, inflammation and fibrosis

Study Design:

Between 2019 and 2022, 116 patients requiring ileocolic resection for Crohn’s disease were randomized to:

Extensive mesenteric excision (EME)

versus

Limited mesenteric excision (LME)

The intention-to-treat population included 111 patients.

Median follow-up was approximately:

72 months with EME

75 months with LME

The primary endpoint was surgical recurrence.

Clinical recurrence, medication exposure and postoperative endoscopic recurrence were also evaluated.

Did Extensive Mesenteric Excision Reduce Surgical Recurrence?

Not significantly.

Surgical recurrence occurred in:

EME: 0%

LME: 4%

P = .495

Clinical recurrence was also numerically lower:

EME: 3%

LME: 11%

but again did not reach statistical significance:

P = .149

Therefore, the trial does not currently establish that EME prevents clinical or surgical recurrence.

The low number of recurrence events substantially limited statistical power.

The More Interesting Finding: Endoscopic Recurrence

Long-term exploratory analysis showed a significantly lower risk of postoperative endoscopic recurrence with EME.

EME reduced the hazard of endoscopic recurrence by approximately 54%:

HR 0.46; 95% CI 0.26–0.81; P = .006

After multivariable analysis, EME remained independently associated with lower recurrence:

HR 0.52; 95% CI 0.30–0.91

What About More Clinically Relevant Endoscopic Recurrence?

The benefit persisted when stricter definitions were used.

For modified endoscopic recurrence (Rutgeerts ≥i2b):

HR 0.50; 95% CI 0.26–0.97

For severe endoscopic recurrence (Rutgeerts i3–i4):

HR 0.20; 95% CI 0.06–0.68

This severe-recurrence finding is particularly noteworthy:

EME was associated with an approximately 80% lower hazard of severe endoscopic recurrence.

End-of-follow-up Rutgeerts scores were also significantly better after EME.

Was the Benefit Simply Due to More Postoperative Medication?

Apparently not.

There was no significant increase in exposure to immunosuppressants or biologic therapy in the EME group.

In fact, patients receiving EME accumulated significantly more time receiving no medication or mesalamine alone:

33.2 vs 14.0 person-years

At the end of follow-up:

29% of EME patients were receiving no treatment or mesalamine

15% of LME patients were in this category

Advanced therapy was used in:

60% with EME

77% with LME

although this difference was not statistically significant.

Thus, the better endoscopic outcome does not appear to be explained by more aggressive postoperative pharmacotherapy.

Why Might Removing the Mesentery Matter?

Crohn’s disease may not be exclusively a disease of the bowel wall.

The mesentery potentially has a dual biological role.

Early in disease:

Creeping fat → containment of microbial translocation → potentially protective

Later:

Mesenteric inflammation + fatty acids + mechanosensitive fibroblasts → fibrosis and stricture formation

Removing diseased mesentery could therefore theoretically reduce one of the biological drivers of postoperative recurrence.

The MESOCOLIC findings support this hypothesis—but do not prove the mechanism.

Why Did MESOCOLIC Differ From the SPICY Trial?

The results contrast with the SPICY trial, which did not demonstrate an endoscopic-recurrence benefit from extended mesenteric resection at 6 months.

An important technical difference may be relevant:

SPICY preserved the ileocolic trunk, whereas MESOCOLIC removed the trunk pedicle.

MESOCOLIC also used a defined mesenteric transition zone to standardize the resection margin.

Therefore, “extended mesenteric excision” may not represent an identical operation across trials.

Does This Mean EME Should Become Standard Crohn’s Surgery?

Not yet.

The primary endpoint—surgical recurrence—was not significantly different.

Furthermore, the long-term endoscopic recurrence analysis was exploratory/post hoc, and the trial was relatively small.

There is also a technical consideration: extensive excision and high ligation of the ileocolic pedicle may be challenging or potentially hazardous when the mesentery is markedly thickened, inflamed and stiff.

The procedure therefore requires appropriate patient selection and surgical expertise.

Clinical Impact:

The study strengthens an evolving concept in Crohn’s surgery:

The mesentery may be biologically relevant tissue rather than merely a structure that provides vascular supply to the diseased bowel.

If larger randomized studies confirm that reductions in severe endoscopic recurrence eventually translate into fewer clinical relapses, less advanced therapy and fewer repeat operations, the extent of mesenteric excision could become an important component of personalized Crohn’s surgery.

Caution:

Several limitations are important:

Small sample size

Very few surgical recurrence events

Endoscopic recurrence analysis was exploratory

Multiple comparisons increase the possibility of type I error

COVID-19 disrupted standardized endoscopic follow-up

Technical expertise may limit generalizability

Long-term clinical benefit remains unproven

Therefore, the striking endoscopic findings should be considered hypothesis-strengthening rather than definitive practice-changing evidence.

Bottom Line:

In the randomized MESOCOLIC trial, extensive mesenteric excision during ileocolic resection did not significantly reduce surgical or clinical recurrence of Crohn’s disease over approximately 6 years. However, it was associated with a 54% lower hazard of endoscopic recurrence and an approximately 80% lower hazard of severe Rutgeerts i3–i4 recurrence, without greater postoperative medication exposure. The results strengthen the concept that the mesentery may influence postoperative Crohn’s biology—but larger adequately powered trials are needed before extensive mesenteric excision becomes routine practice.